Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 452

1.

Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.

Vardy MD, Lindsay R, Scotti RJ, Mikhail M, Richart RM, Nieves J, Zion M, Cosman F.

Am J Obstet Gynecol. 2003 Jul;189(1):81-8.

PMID:
12861143
2.

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.

Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C.

Menopause. 1999 Summer;6(2):134-7.

PMID:
10374220
3.

Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.

Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL.

Obstet Gynecol. 2000 Sep;96(3):359-65.

PMID:
10960626
4.

Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women.

Ismail SI, Bain C, Hagen S.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007063. doi: 10.1002/14651858.CD007063.pub2. Review.

PMID:
20824855
5.

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P.

Fertil Steril. 1998 Dec;70(6):1085-9.

PMID:
9848300
6.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.

Arch Intern Med. 2004 Apr 26;164(8):871-9.

PMID:
15111373
7.

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.

Vogelvang TE, Mijatovic V, Kamp O, Netelenbos JC, Neele SJ, Pines A, Kenemans P, van der Mooren MJ.

Am J Obstet Gynecol. 2002 Apr;186(4):729-36.

PMID:
11967499
8.

Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.

Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr; Study Groups on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream..

Obstet Gynecol. 2003 Feb;101(2):346-52.

PMID:
12576260
9.
10.

Effect of raloxifene on sexual function in postmenopausal women.

Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A.

Climacteric. 2003 Sep;6(3):248-56.

PMID:
14567773
11.

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.

Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.

Menopause. 2010 Mar;17(2):281-9. doi: 10.1097/GME.0b013e3181b7c65f.

PMID:
19779382
12.

Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen.

Goldstein SR, Johnson S, Watts NB, Ciaccia AV, Elmerick D, Muram D.

Menopause. 2005 Mar;12(2):160-4.

PMID:
15772563
13.

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G.

Fertil Steril. 2009 Sep;92(3):1025-38. doi: 10.1016/j.fertnstert.2009.03.113.

PMID:
19635615
14.
16.

Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis.

Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R.

Maturitas. 2004 Jan 20;47(1):47-54.

PMID:
14706765
18.

Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.

Bachmann G, Bobula J, Mirkin S.

Climacteric. 2010 Apr;13(2):132-40. doi: 10.3109/13697130903305627.

PMID:
19863455
19.

Estrogen therapy for severe persistent depressions in women.

Klaiber EL, Broverman DM, Vogel W, Kobayashi Y.

Arch Gen Psychiatry. 1979 May;36(5):550-4.

PMID:
219802
20.

Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.

Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L Jr.

Obstet Gynecol. 2004 Feb;103(2):267-73.

PMID:
14754694
Items per page

Supplemental Content

Support Center